editor
daili
media
warn
loom
pandem
physician
understand
concern
immunosuppress
immunomodul
effect
might
render
patient
receiv
biolog
therapi
suscept
infect
earli
stage
specif
data
suscept
viru
data
infecti
complic
biolog
therapi
pivot
trial
psoriasi
tabl
compar
overal
infect
rate
well
rate
upper
respiratori
infect
nasopharyng
drug
versu
placebo
control
base
publish
data
pivot
trial
tumor
necrosi
factor
blocker
placebocontrol
period
overal
infect
upper
respiratori
infect
increas
compar
placebo
except
etanercept
show
increas
tumor
necrosi
factor
blocker
carri
black
box
warn
concern
infect
ustekinumab
show
small
increas
overal
infect
respiratori
tract
infect
ustekinumab
block
interleukin
il
play
import
role
fight
viral
infect
blocker
show
increas
overal
infect
upper
respiratori
infect
increas
slightli
trial
other
blocker
show
increas
overal
infect
much
increas
could
account
increas
monili
infect
upper
respiratori
infect
increas
slightli
secukinumab
ixekizumab
brodalumab
difficult
extrapol
data
determin
suscept
coronaviru
infect
analysi
flaw
small
number
infect
short
placebocontrol
period
moreov
minor
respiratori
infect
may
underreport
infect
may
report
doubli
upper
respiratori
infect
nasopharyng
nonetheless
data
may
use
decid
whether
continu
biolog
therapi
pandem
know
biolog
therapi
render
patient
suscept
coronaviru
know
precoronaviru
era
respiratori
infect
rate
compar
placebo
convers
discontinu
biolog
result
loss
respons
treatment
reintroduc
even
result
format
antibodi
discontinu
biolog
factor
must
consid
advis
patient
continu
discontinu
biolog
therapi
editor
adult
acn
vulgari
person
age
year
similar
pathophysiolog
mechan
teenag
acn
hormon
regul
cosmet
product
stress
genet
factor
contribut
pathomechan
wide
varieti
treatment
adult
acn
includ
isotretinoin
interestingli
random
control
trial
isotretinoin
compar
acn
treatment
mani
studi
demonstr
improv
adolesc
acn
isotretinoin
treatment
howev
sought
examin
use
treat
acn
women
analyz
patient
chart
femal
patient
year
age
acn
vulgari
diagnos
baylor
clinic
patient
met
inclus
criteria
isotretinoin
treatment
suffici
document
data
compil
electron
medic
record
analyz
use
ibm
spss
statist
version
armonk
ny
averag
age
patient
year
median
age
year
averag
standard
deviat
cumul
dosag
mgkg
durat
standard
deviat
treatment
month
respect
result
show
patient
posit
respons
treatment
experienc
clearanc
lesion
experienc
improv
complet
resolut
frequent
report
side
effect
treatment
cheiliti
xerosi
side
effect
frequenc
summar
tabl
two
patient
discontinu
treatment
side
effect
increas
joint
pain
melasma
flare
treatment
addit
patient
elev
liver
enzym
lipid
panel
result
requir
discontinu
therapi
oral
contracept
pill
ocp
use
form
contracept
patient
ocp
known
therapeut
agent
use
treat
acn
vulgari
analysi
reveal
differ
respons
rate
patient
ocp
nonhormon
contracept
method
p
pearson
degre
freedom
limit
studi
includ
lack
standard
grade
system
acn
well
high
rate
patient
lost
followup
although
patient
return
posttreat
followup
last
note
document
respons
treatment
individu
therefor
includ
studi
high
respons
rate
demonstr
studi
match
studi
suggest
isotretinoin
use
treat
acn
vulgari
adolesc
adult
popul
isotretinoin
treatment
patient
relaps
document
point
lower
seen
previou
studi
despit
high
frequenc
cheiliti
xerosi
patient
elect
discontinu
treatment
side
effect
combin
low
frequenc
side
effect
isotretinoin
consid
welltoler
use
option
physician
consid
treat
acn
adult
femal
patient
